



US00D695123S

(12) **United States Design Patent**  
**Larson et al.**

(10) **Patent No.:** **US D695,123 S**

(45) **Date of Patent:** **\*\* \*Dec. 10, 2013**

(54) **CARTON**

(75) Inventors: **Iver Larson**, Weston, MA (US); **Shilpa Sawhney**, Arlington, MA (US); **Shawn Lynn Goodman**, Everett, MA (US); **Irache B. Visiers**, Arlington, MA (US); **Lilla O. Swan**, Wellesley, MA (US); **Susan Proulx**, Philadelphia, PA (US); **Stephanie DeGraw**, Abington, PA (US); **Michael Wiklund**, Concord, MA (US); **Jonathan Kandler**, Newton, MA (US); **Cynthia Inez Phillips**, Quincy, MA (US); **Christopher Hurff**, Winchester, MA (US)

(73) Assignee: **Millennium Pharmaceuticals, Inc.**, Cambridge, MA (US)

(\*) Notice: This patent is subject to a terminal disclaimer.

(\*\*) Term: **14 Years**

(21) Appl. No.: **29/412,009**

(22) Filed: **Jan. 27, 2012**

(51) **LOC (9) Cl.** ..... **09-01**

(52) **U.S. Cl.**  
USPC ..... **D9/600; D9/432**

(58) **Field of Classification Search**  
USPC ..... D9/600, 652, 414-418, 430-434;  
206/457, 527, 540; 220/890; 229/153  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2,426,484 A \* 8/1947 Buffenbarger ..... 229/153  
2,995,238 A \* 8/1961 Casselman ..... 229/153

D208,332 S \* 8/1967 Marona ..... D9/600  
3,506,181 A \* 4/1970 Farquhar ..... 229/153  
D536,621 S \* 2/2007 Tsutsumi et al. .... D9/432  
D536,965 S \* 2/2007 Levy ..... D9/430  
D552,480 S \* 10/2007 Kusumi et al. .... D9/432  
D597,412 S \* 8/2009 Kusumi ..... D9/432  
D603,700 S \* 11/2009 Paredes et al. .... D9/432  
D612,261 S \* 3/2010 Champion et al. .... D9/600  
D651,908 S \* 1/2012 Boyer et al. .... D9/600  
D651,909 S \* 1/2012 Boyer et al. .... D9/600  
D652,311 S \* 1/2012 Boyer et al. .... D9/600  
D652,314 S \* 1/2012 Boyer et al. .... D9/600  
D652,315 S \* 1/2012 Boyer et al. .... D9/600

**OTHER PUBLICATIONS**

Flovent HFA, Carton for inhalation device sold by GlaxoSmithKline. Believed to be publicly available prior to Jan. 27, 2012. First use date is unknown.

\* cited by examiner

*Primary Examiner* — Sandra Morris

(74) *Attorney, Agent, or Firm* — Honigman Miller Schwartz and Cohn LLP; Douglas H. Siegel; Jonathan P. O'Brien


(57) **CLAIM**

We claim the ornamental design for a carton, as shown and described.

**DESCRIPTION**

FIG. 1 is a perspective elevational view of our inventive carton design;  
FIG. 2 is a front view thereof;  
FIG. 3 is a back view thereof;  
FIG. 4 is a right side view thereof;  
FIG. 5 is a left side view thereof;  
FIG. 6 is a top view thereof; and,  
FIG. 7 is a bottom view thereof.

**1 Claim, 4 Drawing Sheets**










FIG. 1

Reconstitution Information	
SUBCUTANEOUS INJECTION ONLY	INTRAVENOUS INJECTION ONLY
 Add <b>1.4 mL</b> 0.9% Sodium Chloride	 Add <b>3.5 mL</b> 0.9% Sodium Chloride
 To make <b>2.5 mg/mL</b> final concentration	 To make <b>1 mg/mL</b> final concentration

NDC 63020-049-01

**VELCADE<sup>®</sup>**  
(bortezomib) for Injection

**3.5 mg/vial**





Reconstitution Information	
SUBCUTANEOUS INJECTION ONLY	INTRAVENOUS INJECTION ONLY
 Add <b>1.4 mL</b> 0.9% Sodium Chloride	 Add <b>3.5 mL</b> 0.9% Sodium Chloride
 To make <b>2.5 mg/mL</b> final concentration	 To make <b>1 mg/mL</b> final concentration

FIG. 2

**VELCADE<sup>®</sup>**  
(bortezomib) for Injection

See  
Reconstitution  
Information  
on Reverse

NDC 63020-049-01

**VELCADE<sup>®</sup>**  
(bortezomib) for Injection

**3.5 mg/vial**

SINGLE USE VIAL - DISCARD UNUSED PORTION  
FOR INTRAVENOUS OR SUBCUTANEOUS USE

MILLENNIUM

FIG. 3




FIG. 4






FIG. 5



**FIG. 6**



**FIG. 7**